Search

Introduction HPV vaccination is recommended in France for girls aged 14 and for those aged 15–23 before sexual debut or who have become sexually active within the previous year. The first aim was to describe vaccination practice among 14–23-year-old girls visiting a general practitioner. A second objective was to investigate factors associated with starting vaccination among girls aged 14–18, in particular the regular practice of Pap-smear screening (PSS) by their mothers. Methods A cross-sectional study was conducted from June to August 2009. A total of 87 general practitioners from the large Rhone-Alpes region contributed data on 502 girls/women who came for consultation. Results 231 (46.0%) of these girls/women had begun the process of HPV vaccination (68.2%, 56.9% and 18.7% of the 14–16, 17–20 and 21–23-year-olds respectively) of whom 139 (60.2%) had received all three doses. 92 girls/women (39.8%) had received only one or two doses at the time of study. However, in 71 (77.2%) cases, the gap between the last dose received and the time of study was within the between-dose interval recommended in the vaccination schedule. GPs reported that 16 (11.5%) had mentioned side effects following injections. Having a mother who practised regular PSS (Odds Ratio 6.2 [1.5–25.8]), having never lived with a partner (4.6 [1.6–13.5]) and vaccination against hepatitis B (3.2 [1.6–6.1]) were found to be independently correlated with the initiation of HPV vaccination among girls/women aged 14–18 years. Conclusion Two years after the start of the programme, only half of girls/women aged 14–23 years had begun the process of HPV vaccination. HPV vaccination status was correlated with PSS in the mother, family status and hepatitis B vaccination. Such information may help to better target girls who are less likely to be vaccinated.

Objectifs Etudier la valeur pronostique des nodules pulmonaires vus au scanner thoracique chez des enfants atteints de nephroblastome localise (radiographie pulmonaire normale). Sujets / materiels et methodes tous les enfants traites pour un nephroblastome localise unilateral en France dans le protocole SIOP 2001 avant janvier 2009 ont ete analyses. La survie sans rechute pulmonaire (SSRP) a ete comparee (test du Log-Rank) en fonction de la presence ou non de nodules pulmonaires au scanner (groupes N+ vs N-), a l’aide d’une approche boostrap permettant d’equilibrer les effectifs pour la comparaison. Resultats principaux Parmi les 289 patients inclus, 36 etaient N+. Les deux groupes etaient comparables en termes de volume tumoral, âge au diagnostic ; on notait plus de stades III chez les N+ (44% vs 25%). Le taux de rechute pulmonaire etait de 11% chez les N+ vs 6% chez les N-. L’analyse de la SSRP n’a pas mis en evidence de difference significative entre les 2 groupes. Conclusions La puissance statistique de l’analyse etait tres limitee par le faible effectif de N+ (n=36). Une etude prospective avec une definition radiologique des metastases pulmonaires permettrait d’apporter une reponse concernant le pronostic des micrometastases dans le nephroblastome.